Crohn’s fibrosis breakthrough points to new treatment targets

A team led by the University of Edinburgh has revealed a key driver behind Crohn’s disease-related fibrosis, the scarring that can tighten and block the gut. Scientists say clusters of immune cells in the gut trigger surrounding cells to lay down excess collagen, fueling fibrosis and complicating disease management. The finding shifts attention from inflammation alone to the signals that promote scar tissue formation, a major cause of surgery for patients with Crohn's.

Researchers studied intestinal tissue from Crohn’s patients with fibrosis, focusing on the ileum, the last part of the small intestine where the disease often develops. Using archived samples, they mapped changes across the bowel wall and found substantially more scar tissue and immune cell infiltration in affected tissue compared with healthy tissue. Notably, the submucosa, a deeper layer of the wall, showed particular activity.

The team says identifying the cellular signaling pathways linking immune activity to collagen production could guide new therapies that prevent or slow fibrosis, addressing a challenge that current treatments miss. Dr Shahida Din, a gastroenterologist involved in the work, said: "Fibrosis remains one of the most challenging complications of Crohn’s disease because current treatments primarily target inflammation rather than the scarring itself." The findings offer a roadmap for targeting fibrosis rather than just inflammation.

Experts say the discovery could accelerate the development of drugs aimed at interrupting scarring, potentially reducing the need for surgery and improving quality of life for patients. While the work is early, researchers at Edinburgh and collaborating centers are optimistic about translating the insights into therapies that curb fibrosis in Crohn’s and possibly other inflammatory bowel diseases.

#CrohnsBreakthrough, #FibrosisResearch, #GutHealth